BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer

[1]  J. Benítez,et al.  The Molecular Pathology of Hereditary Breast Cancer , 2008, Pathobiology.

[2]  F. Couch,et al.  Response: Re: Molecular Basis for Estrogen Receptor α Deficiency in BRCA1-Linked Breast Cancer , 2007 .

[3]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[4]  M. Stampfer,et al.  Solar flair. , 2003, Molecular Cancer.

[5]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[6]  P. Mullan,et al.  The role of BRCA1 in transcriptional regulation and cell cycle control , 2006, Oncogene.

[7]  Hongyue Dai,et al.  Rosetta error model for gene expression analysis , 2006, Bioinform..

[8]  P. Watson,et al.  BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. , 2005, Cancer research.

[9]  Å. Borg,et al.  Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.

[10]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[11]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.

[12]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[13]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[14]  L. Bégin,et al.  The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.

[15]  C. Perou,et al.  MYC Is Amplified in BRCA1-Associated Breast Cancers , 2004, Clinical Cancer Research.

[16]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[17]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Ouchi,et al.  BRCA1–Sp1 interactions in transcriptional regulation of the IGF‐IR gene , 2003, FEBS letters.

[19]  H. Avraham,et al.  A Novel Tricomplex of BRCA1, Nmi, and c-Myc Inhibits c-Myc-induced Human Telomerase Reverse Transcriptase Gene (hTERT) Promoter Activity in Breast Cancer* , 2002, The Journal of Biological Chemistry.

[20]  A. Ashworth,et al.  Profiling familial breast cancer , 2001, Nature Medicine.

[21]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[22]  L. Bégin,et al.  Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Hongtao Zhang,et al.  BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells , 1998, Oncogene.

[24]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[25]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.